Non-coding RNAs (ncRNAs) are diverse classes of RNA molecules not translated into proteins, which possess intricate regulatory and structural functions. NcRNAs belong to a family of regulatory transcripts that affect every stage of gene expression, from transcription and mRNA stability to mRNA translation. Recent evidence has uncovered critical roles for noncoding RNAs in cancer pathogenesis. For example, variation of specific microRNAs has shown to drive tumorigenesis in human cancer cells and mouse models. Long noncoding RNAs (lncRNAs) have also been related to diverse cancer phenotypes and neurological disorders. NcRNAs are deeply involved in the regulation of key genes that are associated with cancer, representing a promising area for new therapies. This review focuses on ncRNAs, their role in cancer, and the translational implications of noncoding RNA research that may contribute to the development of innovative therapeutic solutions to treat cancer, and improve patients' quality of life and survival.
The noncoding genome represents around 97% of the human genome. NcRNAs can be categorized into distinct classes, based on their biogenesis, size, and biologic function. Long noncoding RNAs (16000), small noncoding RNAs (7500) and pseudogenes (15000) belong to this imense group of genes. The noncoding genome is persistently transcribed. 85% represents transcribed genome versus silent genome (15%). Long noncoding RNAs (lncRNAs) are ncRNAs bigger than 200nt, which are not translated and are seldom expressed. They also have tissue specific expression and lack of ORF and conservation.
Short regulatory ncRNAs (<200 nucleotides) include miRNAs, siRNAs, and piwiassociated RNAs (piRNAs). piRNAs are produced by a long RNA, which is a RNA polymerase II (Pol II) transcript. MicroRNAs (miRNAs) are the best characterized class of short ncRNAs (19-24 nt) , which are present in animals, plants, and algae (BARTEL 2009 ). The first miRNA, lin-4, was discovered in the early 1990s. Lin-4 and let-7 were described as regulators of developmental timing in the nematode (LEE et al. 1993; WIGHTMAN et al. 1993 ; REINHART et al. 2000) . miRNAs are well conserved in both plants and animals, and are thought to be a vital and evolutionarily ancient component of gene regulation (PETERSON et al. 2009 ).
Long regulatory non-coding RNA (lncRNAs) (200-100,000 nucleotides) (GUTSCHNER and DIEDERICHS 2012; PONTING et al. 2009) contribute to the regulation of gene expression at various levels, such as chromatin modification, transcription and post-transcriptional processing. And are functional RNA molecules involved in diverse cellular processes: epigenetic regulation (Xist, H19, Anril, Terra, ecCEBP…), proteostasis (HULC, MEG3, GAS5, PANDA, HOTAIR…), stem cell pool (AKO28326, ES1, ES2,ES3, Linc-ROR,…), cell proliferation (MALAT1, ANRIL, SRA, UCA1, HEIH…), intercellular communication (17A, Lethe, THRIL, TUC339, LNC-IL7R…), and Research November 2017: 33-45 telomere stability (TERC, TERRA…) among others (GRAMMATIKAKIS et al. 2014) . Human lncRNAs annotated by the GENCODE project comprise the largest public dataset containing 15,877 lncRNA genes, although it has been identified a huge number of new lncRNA genes (IYER et al. 2015) .
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Due to advances in sequencing technologies, a growing number of long noncoding RNAs (lncRNAs) have been identified, and many of them have shown to be key regulators of protein coding genes. Analyses of global transcriptome have shown that up to 70% of protein coding genes that have an antisense RNA can act as a key regulator of sense mRNA transcription (KATAYAMA et al. 2005) . Moreover, dysregulation of lncRNAs is linked to various human diseases from neurodegeneration to cancer (WAPINSKI and CHANG 2011) . A number of reports suggest that lncRNAs are critical in epigenetic regulation that can alter histone modifications in cis and trans (RINN and CHANG 2012; SABIN et al. 2013; JOH et al. 2014) . A significant fraction (~20%) of lncRNAs can physically associate with the polycomb repressive complex 2 (PRC2), which suggests lncRNAs play an active role in chromatin modification and gene repression (KHALIL et al. 2009; GUTTMAN et al. 2011) .
Implications of ncRNAs in cancer
Cancer is characterized by uncontrollable cell growth resulting from a complex multistep accumulation of sequential genetic alterations. Previously, it has been shown the role of RNA-protein interactions in the regulation of oncogenic and tumor suppressive genes. However, the precise functions of many individual ncRNAs are still an enigma (POLISENO et al. 2010; KALYANA-SUNDARAM et al. 2012) . Although there is cumulative evidence that ncRNAs are essential for cell proliferation and survival under physiologic conditions, and their deregulation is linked to oncogenesis (see table 1 and 2) (KEUN et al. 2009; CALIN et al. 2007; SPIZZO et al. 2012; LI et al. 2013) .
To date, the role of miRNA in cancer has been far better characterized than lncRNAs, and their expression profiles can be used in the classification of human cancers (LU et al. 2005) . miRNAs can act as tumor suppressors and oncogenes which are down-and up-regulated in cancer, respectively. One of the first oncogenic miRNA described was miR17-92 (see table 1) which has pleiotropic functions in the cell. miR17-92 is overexpressed in lung and colon cancer, lymphoma, multiple myeloma and medulloblastoma (MENDELL 2008) , and its absence induces an increase of the proapoptotic protein Bim and inhibits the pro-B to pre-B cell development (HE et al. 2005) .
In contrast, miR15 and miR-16 are tumorsuppressive miRNAs by the induction of apoptosis of transformed cells and cell cycle regulation. Some studies demonstrated the relation of miR15 and miR16 to chronic lymphocytic leukemias (CALIN et al. 2002) , epithelial malignancies and ovarian cancer (BHATTACHARYA et al. 2009 ). Table 1 also shows other miRNAs with oncogenic and tumor suppressive functions. In addition to cancer-associated miRNAs, Qiao and colleagues described the first evidence of the role of piRNAs in cancer (QIAO et al. 2002) . Hiwi, Piwi family member, is overexpressed in seminomas but not in nonseminomas or in somatic tumors of the adult testis (QIAO et al. 2002) . SnoRNAs are also involved in the beginning of the Prader-Willy syndrome (PWS), and are induced by the genetic loss of the 15q11-q13 locus (normally active only on the paternal allele). This site is characterized by several copies of the HBII-85 snoRNA, whose loss seems to be correlated with the PWS phenotype, both in human and in mice (MOURTADA-MAARABOUNI et al. 2009 ).
Many lncRNAs were first characterized by their repressive functions, including ANRIL, HOTAIR, H19, KCNQ1OT1, and (RINN et al. 2007; YAP et al. 2010; GIBB et al. 2011) (see  table 2 ). These lncRNAs exert their repressive function by connection with histone-modifying or chromatin-remodeling protein complexes (PRENSNER and CHINNAIYAN 2011a) . In addition, they can regulate the expression of some genes related with tumorigenesis (LUO et al. 2001; LUJAMBIO and ESTELLER 2009; MAES et al. 2010) . For example, satellite repeats in heterochromatin are normally repressed and are highly expressed in multiple cancers (TING et al. 2011) . Another lncRNA, HULC, has been shown to be overexpressed in hepatocellular carcinoma, in which may act as miRNA sponge, and in colorectal cancer. HULC is implicated in liver metastasis (MATOUK et al. 2007) . These examples illustrate the possibility of the role of ncRNAs as biomarkers or therapeutic targets to cancer. In summary, LncRNAs are implicated in multiple functions during cancer, such as Over the last several years, approaches to demonstrate the important role of ncRNAs have been published. Similar observations have been also made using murine models. Some examples are described above:
(1) The Metastasis-Associated-in-Lung Adenocarcinoma -Transcript-1 (MALAT-1) is an ncRNA that is highly expressed in several tumor types. The overexpression and RNA interference (RNAi) approaches were used for the analysis of the biological functions of MALAT-1 RNA.
In non-small cell lung cancer (NSCLC), MALAT-1 displays the strongest association with genes involved in cancer like cellular growth, movement, proliferation, signaling, and immune regulation (SCHMIDT et al. 2011) .
(2) The overexpression of AK081227 mediated by the Mecp2 loss is associated with the downregulation of its host coding protein gene, the gamma-aminobutyric acid receptor subunit Rho 2 (Gabrr2). The transcriptional dysregulation of lncRNA upon Mecp2 loss contributes to the neurological phenotype of Rett syndrome and highlights the complex interaction between ncRNAs and coding-RNAs (PETAZZI et al. 2013) .
(3) The knockdown of the antisense noncoding mitochondrial RNAs (ASncmtRNAs) generates a new murine noncoding mitochondrial RNAs (ncmtRNAs) model, which could be potent targets for melanoma therapy. This has been the first potential non-nuclear target for melanoma therapy (LOBOS-GONZALEZ et al. 2016) . MARCUCCI et al. 2008 ). In addition, it has been described the correlation between circulating miRNA levels and the response to a given anticancer agent (HUI et al. 2009 ). The best example is miR-21, which is upregulated in human cancers and the levels of circulating miR-21 were higher in patients with hormone-refractory prostate cancer, whose disease was resistant to docetaxel-based chemotherapy, in comparison with patients who had chemo sensitive disease (ZHANG et al. 2011) .
The study of lncRNAs is a fast growing field of research. HOTAIR can be a potential biomarker for the existence of lymph node metastasis in hepatocellular carcinoma (HCC) (GENG et al. 2011) . HULC (PANZITT et al. 2007) or other lncRNA, MALAT1 (LAI et al. 2012) can be used as a prognostic markers. One of the lncRNAs utilized in a clinical test is PCA3 (prostate cancer associated), which can be detected in urine samples obtained after a prostatic massage (MARKS et al. 2007) . The detection of both miRNAs and lncRNAs in body fluids, such as blood or urine, and its use as non-invasive cancer biomarkers is an active area of research due to their high stability and resistance to storage and handling (TINZL et al. 2004; MITCHELL et al. 2008) .
2.-ncRNAs in cancer therapy
As many miRNA and lncRNA are deregulated in cancer, many researchers now focus on their role as therapeutic targets (AL OLABY and AZZAZY 2011) . miRNA therapy is being used to down-regulate or block the function of oncogenic miRNAs or up-regulate their tumor-suppressive function. There are several approaches to control oncogenic miRNA expression: by introducing mRNAs targeting specific miRNAs or by using antisense singlestranded oligonucleotides complementary to miRNA, which acts as miRNA sponges and miRNA antagonists, respectively (MERIKALLIO et al. 2011; DIALLO et al. 2011); BRODERICK et al. 2011) . Alternatively, new techniques to re-express miRNAs with tumor suppressor roles are constantly emerging, as the administration of synthetic miRNA becomes a common therapy (TRANG et al. 2010) . It has also been reported the successful systemic delivery of miRNAs as anti-cancer approaches in preclinical models using liposomes viral vectors (KOTA et al. 2009; RAI et al. 2011 ) and nanoparticles (SU et al. 2011) . A better understanding of the molecular mechanisms of lncRNAs in cancer might lead to development of more effective cancer therapies in the near future. Recently, it has been published the role of 7SL ncRNA in the treatment of cancers. This function could be related with tumor suppressor p53, which suggest that targeting 7SL may be effective in the treatment of cancers with reduced p53 levels . A more recent report demonstrated the link between miR-155 and SMARCA4 expression levels in theprognosis of patients with lung tumors. This seems to be be due to oncogenic properties of miR-155 in lung cancer by its role inhibiting SMARCA4 (COIRA et al. 2015) .
NcRNAs can also be related to chemo resistance by damaging the response through cell cycle arrest, enhanced DNA damage repair and inhibition of apoptosis (LIPOVICH et al. 2010; GOLDMAN 2003; HARRIES 2012) . Several lncRNAs in cancer can upregulate drug resistance gene (CUDR) and antagonize the apoptotic effect of cisplatin in bladder cancer cells (D'ADDA DI FAGAGNA 2008) . Moreover, the growth arrest-specific 5 lncRNA Gas5, which contributes to glucocorticoid resistance, is associated with therapeutic resistance (YANG et al. 2012 ) (KINO et al. 2010) . PANDA is increased in a subset of breast cancer cells that contributes to anthracycline resistance, a crucial component of breast cancer chemotherapy (SOTILLO and THOMAS-TIKHONENKO 2011). They are also many p53-regulated lncRNAs, which are induced in response to DNA damage and promote chemo resistance (AMIT and HOCHBERG 2010) . HULC lncRNA may also act as an endogenous sponge to reduce miRNA levels and inhibit their functional activity (PANZITT et al. 2007 ). This functional and structural innovation of lncRNAs offers potential as anticancer therapeutics that can prevent the emergence of drug resistance commonly seen with current agents (MALEK et al. 2014) .
Conclusions
Highly relevant functions of ncRNAs have been recently demonstrated. Based on recent discoveries in genome editing in simple organisms, similar technologies might soon become available to the study of mammalian systems (HOCKEMEYER et al. 2011); (WANG et al. 2013); (JINEK et al. 2012) . A key area of research would be 1) to link lncRNA-miRNA interactions and human diseases, and 2) to functionally characterize other lncRNAs (e.g., very long lncRNAs, pseudo genes, antisense RNAs) and other small RNAs (e.g., piRNAs, siRNAs, snoRNAs 
